10-Q · 2026-11-05
Monte Rosa Therapeutics, Inc. releases Q3 financial results, showcasing progress in R&D and collaborations in the biological products sector.
| Name | Monte Rosa Therapeutics, Inc. |
|---|---|
| CIK | 0001826457 |
| Tickers | GLUE |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company |
| SIC | 2836 Biological Products, (No Diagnostic Substances) |
| EIN | 000000000 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 617-949-2643 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Monte Rosa Therapeutics, Inc. releases Q3 financial results, showcasing progress in R&D and collaborations in the biological products sector.
Monte Rosa Therapeutics released its financial results for Q3 2026, providing insights into its operational performance and future strategies.
405 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001193125-26-464030 | 005-92649 | 261563381 | 34 | 17931 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000902664-26-004583 | 005-92649 | 261561441 | 34 | 10883 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000921895-26-003182 | 005-92649 | 261561246 | 34 | 23693 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000080255-26-000719 | 005-92649 | 261556485 | 34 | 7763 | |||
| 2026-11-05 | 10-Q | 10-Q | 0001193125-26-448568 | 001-40522 | 261524757 | 34 | 10956704 | 1 | 1 | |
| 2026-11-05 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-448527 | 001-40522 | 261524686 | 34 | 498219 | 1 | 1 |
| 2026-10-06 | 4 | 4 | 0001193125-26-415540 | 4922 | ||||||
| 2026-10-01 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-26-409833 | 001-40522 | 261428946 | 34 | 21650261 | 1 | 1 |
| 2026-09-08 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-26-384360 | 001-40522 | 261363342 | 34 | 246414 | 1 | 1 |
| 2026-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000919574-26-005533 | 005-92649 | 261282253 | 34 | 16396 | |||
| 2026-08-14 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000902664-26-003506 | 005-92649 | 261281587 | 34 | 15113 | |||
| 2026-08-06 | 10-Q | 10-Q | 0001193125-26-336711 | 001-40522 | 261245941 | 34 | 10781591 | 1 | 1 | |
| 2026-08-06 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-336681 | 001-40522 | 261245891 | 34 | 499801 | 1 | 1 |
| 2026-07-17 | 4 | 4 | 0001193125-26-307791 | 5090 | ||||||
| 2026-07-16 | 4 | 4 | 0001193125-26-306110 | 9080 | ||||||
| 2026-07-16 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-007144 | 001-40522 | 261180402 | 33 | 6819 | |||
| 2026-07-15 | 144 | xsl144X01/primary_doc.xml | 0001969223-26-000786 | 001-40522 | 261177519 | 33 | 6985 | |||
| 2026-07-08 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000080255-26-000442 | 005-92649 | 261161374 | 34 | 7765 | |||
| 2026-07-07 | 4 | 4 | 0001193125-26-297558 | 10303 | ||||||
| 2026-07-06 | 4 | 4 | 0001193125-26-296490 | 9364 | ||||||
| 2026-07-06 | SCHEDULE 13D/A | xslSCHEDULE_13D_X02/primary_doc.xml | 0001072613-26-000558 | 005-92649 | 261157188 | 34 | 88067 | |||
| 2026-07-01 | 4 | 4 | 0001193125-26-292767 | 8571 | ||||||
| 2026-06-30 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006665 | 001-40522 | 261141061 | 33 | 6933 | |||
| 2026-06-30 | 4 | 4 | 0001193125-26-290486 | 8387 | ||||||
| 2026-06-30 | 4 | 4 | 0001193125-26-290484 | 14161 | ||||||
| 2026-06-29 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006612 | 001-40522 | 261136444 | 33 | 6215 | |||
| 2026-06-29 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006574 | 001-40522 | 261135658 | 33 | 5503 | |||
| 2026-06-25 | 4 | 4 | 0001193125-26-282740 | 20551 | ||||||
| 2026-06-25 | 4 | 4 | 0001193125-26-282735 | 8557 | ||||||
| 2026-06-25 | 4 | 4 | 0001193125-26-282736 | 8398 | ||||||
| 2026-06-24 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006456 | 001-40522 | 261116332 | 33 | 5730 | |||
| 2026-06-23 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006428 | 001-40522 | 261111400 | 33 | 5365 | |||
| 2026-06-23 | 144 | xsl144X01/primary_doc.xml | 0001969223-26-000720 | 001-40522 | 261111033 | 33 | 6353 | |||
| 2026-06-23 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006406 | 001-40522 | 261111005 | 33 | 6976 | |||
| 2026-06-18 | 4 | 4 | 0001193125-26-275806 | 8557 | ||||||
| 2026-06-18 | 4 | 4 | 0001193125-26-275805 | 8375 | ||||||
| 2026-06-17 | 144 | xsl144X01/primary_doc.xml | 0001969223-26-000711 | 001-40522 | 261098254 | 33 | 5722 | |||
| 2026-06-12 | 4 | 4 | 0001193125-26-269885 | 5385 | ||||||
| 2026-06-12 | 4 | 4 | 0001193125-26-269365 | 5530 | ||||||
| 2026-06-12 | 4 | 4 | 0001193125-26-269354 | 5472 | ||||||
| 2026-06-12 | 4 | 4 | 0001193125-26-269378 | 5474 | ||||||
| 2026-06-12 | 4 | 4 | 0001193125-26-269349 | 5485 | ||||||
| 2026-06-12 | 4 | 4 | 0001193125-26-269348 | 5455 | ||||||
| 2026-06-12 | 4 | 4 | 0001193125-26-269368 | 5478 | ||||||
| 2026-06-11 | 8-K | 8-K | 5.07 | 0001193125-26-267465 | 001-40522 | 261082941 | 34 | 188290 | 1 | 1 |
| 2026-06-02 | 4 | 4 | 0001193125-26-253472 | 7172 | ||||||
| 2026-06-02 | 144/A | xsl144X01/primary_doc.xml | 0001965301-26-000067 | 001-40522 | 261053868 | 33 | 5764 | |||
| 2026-06-01 | 144 | xsl144X01/primary_doc.xml | 0001965301-26-000066 | 001-40522 | 261051327 | 33 | 6289 | |||
| 2026-06-01 | 4 | 4 | 0001193125-26-251395 | 8874 | ||||||
| 2026-05-29 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-005288 | 001-40522 | 261044819 | 33 | 5022 | |||
| 2026-05-28 | 4 | 4 | 0001193125-26-245728 | 8557 | ||||||
| 2026-05-27 | 144 | xsl144X01/primary_doc.xml | 0001969223-26-000596 | 001-40522 | 261026017 | 33 | 5091 | |||
| 2026-05-26 | 4 | 4 | 0001193125-26-239240 | 8557 | ||||||
| 2026-05-22 | 4 | 4 | 0001193125-26-236840 | 8076 | ||||||
| 2026-05-22 | 144 | xsl144X01/primary_doc.xml | 0001969223-26-000590 | 001-40522 | 261013477 | 33 | 4460 | |||
| 2026-05-21 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-004881 | 001-40522 | 261008257 | 33 | 4752 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001193125-26-226862 | 005-92649 | 26988163 | 34 | 17764 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-062588 | 005-92649 | 26987922 | 34 | 16036 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000921895-26-001394 | 005-92649 | 26987406 | 34 | 25182 | |||
| 2026-05-07 | 10-Q | 10-Q | 0001193125-26-210358 | 001-40522 | 26950890 | 34 | 9174434 | 1 | 1 | |
| 2026-05-07 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-210298 | 001-40522 | 26950803 | 34 | 453240 | 1 | 1 |
| 2026-05-05 | 4 | 4 | 0001193125-26-206344 | 5267 | ||||||
| 2026-05-01 | 144 | xsl144X01/primary_doc.xml | 0001965301-26-000046 | 001-40522 | 26933526 | 33 | 5680 | |||
| 2026-04-29 | ARS | ARS | 0001193125-26-191481 | 001-40522 | 26915770 | 34 | 20570501 | |||
| 2026-04-29 | DEFA14A | DEFA14A | 0001193125-26-191451 | 001-40522 | 26915677 | 34 | 4963350 | 1 | 1 | |
| 2026-04-29 | DEF 14A | DEF 14A | 0001193125-26-191439 | 001-40522 | 26915599 | 34 | 12776457 | 1 | 1 | |
| 2026-04-22 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001193125-26-170903 | 005-92649 | 26884880 | 34 | 36349 | |||
| 2026-04-16 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003550 | 001-40522 | 26867594 | 33 | 8457 | |||
| 2026-04-15 | 4 | 4 | 0001193125-26-156981 | 5073 | ||||||
| 2026-04-14 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003455 | 001-40522 | 26861300 | 33 | 5553 | |||
| 2026-04-13 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003392 | 001-40522 | 26857876 | 33 | 9461 | |||
| 2026-04-10 | 4 | 4 | 0001193125-26-151254 | 5090 | ||||||
| 2026-04-09 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003347 | 001-40522 | 26851611 | 33 | 4737 | |||
| 2026-04-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003308 | 001-40522 | 26848184 | 33 | 6967 | |||
| 2026-04-07 | 4 | 4 | 0001193125-26-145545 | 7415 | ||||||
| 2026-04-07 | 3 | 3 | 0001193125-26-145520 | 26451 | ||||||
| 2026-03-19 | SCHEDULE 13D/A | xslSCHEDULE_13D_X02/primary_doc.xml | 0001072613-26-000294 | 005-92649 | 26774214 | 34 | 78601 | |||
| 2026-03-17 | S-8 | S-8 | 0001193125-26-110712 | 333-294401 | 26767021 | 33 | 783915 | 1 | 1 | |
| 2026-03-17 | 10-K | 10-K | 0001193125-26-109360 | 001-40522 | 26759072 | 34 | 35843474 | 1 | 1 | |
| 2026-03-17 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-109353 | 001-40522 | 26759058 | 34 | 516522 | 1 | 1 |
| 2026-03-05 | 4 | 4 | 0001193125-26-094296 | 4781 | ||||||
| 2026-03-04 | 4 | 4 | 0001193125-26-091733 | 5131 | ||||||
| 2026-03-04 | 144 | xsl144X01/primary_doc.xml | 0001193125-26-091704 | 001-40522 | 26722232 | 33 | 6493 | |||
| 2026-03-02 | 4 | 4 | 0001193125-26-085677 | 13214 | ||||||
| 2026-03-02 | 144 | xsl144X01/primary_doc.xml | 0001965301-26-000022 | 001-40522 | 26708084 | 33 | 5679 | |||
| 2026-03-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-001966 | 001-40522 | 26707809 | 33 | 6222 | |||
| 2026-02-27 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-001887 | 001-40522 | 26700153 | 33 | 5483 | |||
| 2026-02-24 | 4 | 4 | 0001193125-26-066955 | 4420 | ||||||
| 2026-02-23 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-001676 | 001-40522 | 26666700 | 33 | 7243 | |||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000921895-26-000461 | 005-92649 | 26641416 | 34 | 23712 | |||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-26-016412 | 005-92649 | 26641227 | 34 | 15011 | |||
| 2026-02-11 | S-3ASR | S-3ASR | 0001193125-26-046690 | 333-293389 | 26621364 | 33 | 1276437 | 1 | 1 | |
| 2026-02-10 | 8-K | 8-K | 5.02 | 0001193125-26-044616 | 001-40522 | 26615804 | 34 | 168146 | 1 | 1 |
| 2026-01-21 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001012975-26-000062 | 005-92649 | 26545595 | 34 | 16061 | |||
| 2026-01-09 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-26-009005 | 001-40522 | 26523446 | 34 | 677062 | 1 | 1 |
| 2026-01-09 | 424B5 | 424B5 | 0001193125-26-009001 | 333-285942 | 26523430 | 33 | 655453 | |||
| 2026-01-09 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001193125-26-008951 | 005-92649 | 26523282 | 34 | 18564 | |||
| 2026-01-09 | 4 | 4 | 0001193125-26-008902 | 8938 | ||||||
| 2026-01-08 | 144/A | xsl144X01/primary_doc.xml | 0001965301-26-000002 | 001-40522 | 26519031 | 33 | 5146 | |||
| 2026-01-07 | 144 | xsl144X01/primary_doc.xml | 0001965301-26-000001 | 001-40522 | 26516389 | 33 | 4457 | |||
| 2026-01-07 | 8-K | 8-K | 8.01,9.01 | 0001193125-26-006341 | 001-40522 | 26515910 | 34 | 169018 | 1 | 1 |
| 2026-01-07 | 424B5 | 424B5 | 0001193125-26-006297 | 333-285942 | 26515778 | 33 | 657328 | |||
| 2026-01-07 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-26-005420 | 001-40522 | 26513948 | 34 | 14037425 | 1 | 1 |
| 2026-01-05 | 4 | 4 | 0001193125-26-002406 | 9454 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-002401 | 9464 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-002390 | 5280 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-002389 | 9423 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-002386 | 9623 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-002385 | 9444 | ||||||
| 2026-01-05 | 144 | xsl144X01/primary_doc.xml | 0001193125-26-002369 | 001-40522 | 26505752 | 33 | 4546 | |||
| 2025-12-16 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-319981 | 001-40522 | 251573356 | 34 | 12173587 | 1 | 1 |
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000080255-25-000838 | 005-92649 | 251483462 | 34 | 7647 | |||
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-004946 | 005-92649 | 251481692 | 34 | 10067 | |||
| 2025-11-12 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001193125-25-277603 | 005-92649 | 251472863 | 34 | 17212 | |||
| 2025-11-06 | 10-Q | 10-Q | 0001193125-25-268045 | 001-40522 | 251456093 | 34 | 12247925 | 1 | 1 | |
| 2025-11-06 | 8-K | 8-K | 2.02,7.01,9.01 | 0001193125-25-268042 | 001-40522 | 251456079 | 34 | 500391 | 1 | 1 |
| 2025-10-31 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000102909-25-000255 | 005-92649 | 251438824 | 34 | 6300 | |||
| 2025-10-17 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001193125-25-242555 | 005-92649 | 251401160 | 34 | 115667 | |||
| 2025-10-03 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001012975-25-000601 | 005-92649 | 251372802 | 34 | 29309 | |||
| 2025-09-15 | 8-K | 8-K | 1.01,7.01,9.01 | 0001193125-25-202760 | 001-40522 | 251313152 | 34 | 215507 | 1 | 1 |
| 2025-08-21 | UPLOAD | filename1.pdf | 0000000000-25-008933 | 001-40522 | 39744 | |||||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-003581 | 005-92649 | 251214272 | 34 | 10670 | |||
| 2025-08-07 | 10-Q | 10-Q | 0000950170-25-104550 | 001-40522 | 251191539 | 34 | 10451389 | 1 | 1 | |
| 2025-08-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-104545 | 001-40522 | 251191516 | 34 | 472502 | 1 | 1 |
| 2025-07-22 | CORRESP | filename1.htm | 0000950170-25-097510 | 247371 | ||||||
| 2025-07-15 | UPLOAD | filename1.pdf | 0000000000-25-007429 | 001-40522 | 43746 | |||||
| 2025-06-16 | 4 | 4 | 0000950170-25-086727 | 35296 | ||||||
| 2025-06-16 | 4 | 4 | 0000950170-25-086704 | 5318 | ||||||
| 2025-06-16 | 4 | 4 | 0000950170-25-086703 | 5335 | ||||||
| 2025-06-16 | 4 | 4 | 0000950170-25-086702 | 5348 | ||||||
| 2025-06-16 | 4 | 4 | 0000950170-25-086701 | 5341 | ||||||
| 2025-06-16 | 4 | 4 | 0000950170-25-086700 | 5323 | ||||||
| 2025-06-16 | 4 | 4 | 0000950170-25-086699 | 5397 | ||||||
| 2025-06-13 | 8-K | 8-K | 5.07 | 0000950170-25-086129 | 001-40522 | 251046364 | 34 | 187976 | 1 | 1 |
| 2025-06-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-001639 | 005-92649 | 251029175 | 34 | 11501 | |||
| 2025-06-04 | 4 | 4 | 0000950170-25-081637 | 5278 | ||||||
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000921895-25-001549 | 005-92649 | 25954281 | 34 | 23700 | |||
| 2025-05-08 | 10-Q | 10-Q | 0000950170-25-066372 | 001-40522 | 25923835 | 34 | 8290589 | 1 | 1 | |
| 2025-05-08 | 8-K | 8-K | 2.02,7.01,9.01 | 0000950170-25-066370 | 001-40522 | 25923831 | 34 | 37337187 | 1 | 1 |
| 2025-04-25 | ARS | ARS | 0000950170-25-058691 | 001-40522 | 25873736 | 34 | 33762907 | |||
| 2025-04-25 | DEFA14A | DEFA14A | 0000950170-25-058689 | 001-40522 | 25873705 | 34 | 3414928 | |||
| 2025-04-25 | DEF 14A | DEF 14A | 0000950170-25-058686 | 001-40522 | 25873629 | 34 | 13547644 | 1 | 1 | |
| 2025-04-16 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000919574-25-002493 | 005-92649 | 25843690 | 34 | 17440 | |||
| 2025-03-31 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-25-000901 | 333-285942 | 25796314 | 33 | 1780 | ||
| 2025-03-27 | CORRESP | filename1.htm | 0001193125-25-065485 | 6552 | ||||||
| 2025-03-26 | UPLOAD | filename1.pdf | 0000000000-25-003255 | 333-285942 | 40147 | |||||
| 2025-03-25 | 4 | 4 | 0000950170-25-044633 | 4363 | ||||||
| 2025-03-20 | S-3 | S-3 | 0001193125-25-058423 | 333-285942 | 25754721 | 33 | 1264877 | |||
| 2025-03-20 | S-8 | S-8 | 0000950170-25-042346 | 333-285940 | 25754671 | 33 | 191338 | |||
| 2025-03-20 | 10-K | 10-K | 0000950170-25-042344 | 001-40522 | 25754659 | 34 | 31765596 | 1 | 1 | |
| 2025-03-20 | 8-K | 8-K | 2.02,7.01,9.01 | 0000950170-25-042319 | 001-40522 | 25754464 | 34 | 38254651 | 1 | 1 |
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-000984 | 005-92649 | 25623914 | 34 | 10710 | |||
| 2025-02-04 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0002012383-25-000642 | 005-92649 | 25587840 | 34 | 11825 | |||
| 2025-01-31 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000921895-25-000213 | 005-92649 | 25579936 | 34 | 38662 | |||
| 2025-01-30 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000932471-25-000196 | 005-92649 | 25575672 | 34 | 6179 | |||
| 2025-01-10 | 8-K | 8-K | 2.02,7.01,9.01 | 0000950170-25-003776 | 001-40522 | 25520353 | 34 | 37719733 | 1 | 1 |
| 2025-01-06 | 4 | 4 | 0000950170-25-002105 | 7329 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002103 | 7329 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002102 | 7494 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002101 | 7339 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002100 | 7297 | ||||||
| 2025-01-06 | 4 | 4 | 0000950170-25-002099 | 7319 | ||||||
| 2024-12-13 | 4 | 4 | 0000950170-24-136056 | 5276 | ||||||
| 2024-12-13 | 3 | 3 | 0000950170-24-136055 | 14837 | ||||||
| 2024-12-13 | 8-K | 8-K | 5.02 | 0000950170-24-136042 | 001-40522 | 241546777 | 34 | 172010 | 1 | 1 |
| 2024-12-05 | 8-K | 8-K | 7.01,8.01,9.01 | 0000950170-24-133525 | 001-40522 | 241527806 | 34 | 37588463 | 1 | 1 |
| 2024-11-14 | SC 13G/A | glue13gasep24.txt | 0000080255-24-001467 | 005-92649 | 34 | 7155 | ||||
| 2024-11-12 | SC 13G/A | filing.txt | 0000315066-24-002827 | 005-92649 | 241444867 | 34 | 8235 | |||
| 2024-11-07 | 10-Q | 10-Q | 0000950170-24-122780 | 001-40522 | 241433117 | 34 | 7969934 | 1 | 1 | |
| 2024-11-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-122766 | 001-40522 | 241433077 | 34 | 468288 | 1 | 1 |
| 2024-10-30 | SC 13D/A | SC 13D/A | 0001193125-24-247656 | 005-92649 | 241411408 | 34 | 113360 | |||
| 2024-10-30 | 4 | 4 | 0000950170-24-119051 | 38188 | ||||||
| 2024-10-28 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000523 | 001-40522 | 241400880 | 33 | 4461 | |||
| 2024-10-28 | 8-K | 8-K | 1.01,7.01,9.01 | 0000950170-24-117567 | 001-40522 | 241398411 | 34 | 225394 | 1 | 1 |
| 2024-09-24 | SC 13D/A | SC 13D/A | 0001193125-24-224875 | 005-92649 | 241320749 | 34 | 112359 | |||
| 2024-09-24 | 4 | 4 | 0000950170-24-109112 | 16024 | ||||||
| 2024-09-13 | 4 | 4 | 0000950170-24-106532 | 20002 | ||||||
| 2024-09-13 | 4 | 4 | 0000950170-24-106387 | 5597 | ||||||
| 2024-08-12 | SC 13D/A | NEW ENTERPRISE ASSOCIATES 17, L.P. -- MONTE ROSA THERAPEUTICS 13D/A(#2) | 0001072613-24-000618 | 005-92649 | 241198352 | 34 | 452279 | |||
| 2024-08-12 | SC 13D/A | SC 13D/A | 0001193125-24-198980 | 005-92649 | 241197850 | 34 | 112172 | |||
| 2024-08-08 | 10-Q | 10-Q | 0000950170-24-093296 | 001-40522 | 241185966 | 34 | 7753644 | 1 | 1 | |
| 2024-08-08 | 8-K | 8-K | 2.02 | 0000950170-24-093294 | 001-40522 | 241185959 | 34 | 465278 | 1 | 1 |
| 2024-07-09 | 4 | 4 | 0000950170-24-082416 | 5285 | ||||||
| 2024-06-27 | 8-K | 8-K | 7.01,9.01 | 0000950170-24-078159 | 001-40522 | 241075357 | 34 | 220784 | 1 | 1 |
| 2024-06-13 | 4 | 4 | 0000950170-24-073265 | 32889 | ||||||
| 2024-06-13 | 4 | 4 | 0000950170-24-073064 | 5404 | ||||||
| 2024-06-13 | 4 | 4 | 0000950170-24-073073 | 5348 | ||||||
| 2024-06-13 | 4 | 4 | 0000950170-24-073063 | 5330 | ||||||
| 2024-06-13 | 4 | 4 | 0000950170-24-073062 | 5342 | ||||||
| 2024-06-13 | 4 | 4 | 0000950170-24-073059 | 5355 | ||||||
| 2024-06-12 | 8-K | 8-K | 5.07 | 0000950170-24-072407 | 001-40522 | 241038337 | 34 | 182380 | 1 | 1 |
| 2024-06-05 | 4 | 4 | 0000950170-24-069310 | 5287 | ||||||
| 2024-06-05 | 4 | 4 | 0000950170-24-069309 | 5370 | ||||||
| 2024-06-05 | 4 | 4 | 0000950170-24-069308 | 5378 | ||||||
| 2024-06-05 | 4 | 4 | 0000950170-24-069307 | 5398 | ||||||
| 2024-06-05 | 3 | 3 | 0000950170-24-069283 | 20329 | ||||||
| 2024-06-05 | 3 | 3 | 0000950170-24-069279 | 20303 | ||||||
| 2024-05-30 | 8-K | 8-K | 5.02,7.01,9.01 | 0001193125-24-149802 | 001-40522 | 241000706 | 34 | 175250 | 1 | 1 |
| 2024-05-16 | 8-K | 8-K | 1.01,9.01 | 0001193125-24-140533 | 001-40522 | 24955534 | 34 | 657190 | 1 | 1 |
| 2024-05-16 | 424B5 | 424B5 | 0001193125-24-140518 | 333-266003 | 24955445 | 33 | 573187 | |||
| 2024-05-15 | 424B5 | 424B5 | 0001193125-24-139354 | 333-266003 | 24950253 | 33 | 573201 | |||
| 2024-05-13 | SC 13D/A | NEW ENTERPRISE ASSOCIATES 17, L.P. -- MONTE ROSA THERAPEUTICS 13D/A(#1) | 0001072613-24-000471 | 005-92649 | 24941114 | 34 | 476792 | |||
| 2024-05-09 | 10-Q | 10-Q | 0000950170-24-056288 | 001-40522 | 24928624 | 34 | 6693730 | 1 | 1 | |
| 2024-05-09 | 8-K | 8-K | 2.02,7.01,9.01 | 0000950170-24-056253 | 001-40522 | 24928502 | 34 | 36452109 | 1 | 1 |
| 2024-05-02 | 8-K | 8-K | 5.02,7.01,9.01 | 0000950170-24-052055 | 001-40522 | 24908039 | 34 | 208749 | 1 | 1 |
| 2024-05-01 | 144 | xsl144X01/primary_doc.xml | 0001974158-24-000034 | 001-40522 | 24903429 | 33 | 11336 | |||
| 2024-04-26 | ARS | ARS | 0000950170-24-049093 | 001-40522 | 24883575 | 34 | 13892902 | |||
| 2024-04-26 | DEFA14A | DEFA14A | 0000950170-24-049075 | 001-40522 | 24883476 | 34 | 3298610 | |||
| 2024-04-26 | DEF 14A | DEF 14A | 0000950170-24-049065 | 001-40522 | 24883362 | 34 | 7941867 | |||
| 2024-04-10 | 144 | xsl144X01/primary_doc.xml | 0001974158-24-000022 | 001-40522 | 24836093 | 33 | 4396 | |||
| 2024-04-10 | SC 13G/A | glue13gamar24.txt | 0000080255-24-000836 | 005-92649 | 34 | 7126 | ||||
| 2024-03-14 | S-8 | S-8 | 0000950170-24-031455 | 333-277929 | 24750151 | 33 | 169502 | |||
| 2024-03-14 | 10-K | 10-K | 0000950170-24-031150 | 001-40522 | 24747948 | 34 | 24407553 | 1 | 1 | |
| 2024-03-14 | 8-K | 8-K | 2.02,7.01 | 0000950170-24-031138 | 001-40522 | 24747899 | 34 | 31587485 | 1 | 1 |
| 2024-02-14 | SC 13G | SC 13G | 0001104659-24-023735 | 005-92649 | 24638764 | 34 | 98737 | |||
| 2024-02-14 | SC 13G/A | AMENDMENT NO. 3 | 0000929638-24-000644 | 005-92649 | 24636508 | 34 | 150019 | |||
| 2024-02-14 | SC 13G/A | us61225m1027_021424.txt | 0001086364-24-007037 | 005-92649 | 24634347 | 34 | 12545 | |||
| 2024-02-14 | SC 13G/A | glue13gadec23.txt | 0000080255-24-000762 | 005-92649 | 34 | 7129 | ||||
| 2024-02-14 | SC 13G/A | MONTE ROSA THERAPEUTICS, INC. | 0000902664-24-001601 | 005-92649 | 24632983 | 34 | 59009 | |||
| 2024-02-09 | SC 13G/A | filing.txt | 0000315066-24-001315 | 005-92649 | 24611866 | 34 | 8236 | |||
| 2024-01-08 | 8-K | 8-K | 7.01,9.01 | 0000950170-24-002696 | 001-40522 | 24518367 | 34 | 26731406 | 1 | 1 |
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000767 | 5593 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000768 | 6437 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000766 | 5714 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000764 | 6420 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000769 | 5607 | ||||||
| 2024-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-24-000765 | 8073 | ||||||
| 2023-11-09 | SC 13D/A | SC 13D/A | 0001193125-23-274637 | 005-92649 | 231393912 | 34 | 122198 | |||
| 2023-11-09 | 10-Q | 10-Q | 0000950170-23-061995 | 001-40522 | 231392236 | 34 | 8999706 | 1 | 1 | |
| 2023-11-09 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-061530 | 001-40522 | 231390059 | 34 | 513998 | 1 | 1 |
| 2023-10-26 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-23-264162 | 001-40522 | 231350898 | 34 | 437017 | 1 | 1 |
| 2023-10-26 | 424B5 | 424B5 | 0001193125-23-264155 | 333-266003 | 231350851 | 33 | 486319 | |||
| 2023-10-17 | 8-K | 8-K | 1.01,7.01,8.01 | 0000950170-23-053653 | 001-40522 | 231328464 | 34 | 41943859 | 1 | 1 |
| 2023-08-18 | 3 | FORM 3 SUBMISSION | 0001209191-23-046513 | 12457 | ||||||
| 2023-08-15 | 144 | xsl144X01/primary_doc.xml | 0001963745-23-000051 | 001-40522 | 231175763 | 33 | 4398 | |||
| 2023-08-10 | 10-Q | 10-Q | 0000950170-23-040959 | 001-40522 | 231157182 | 34 | 8075642 | 1 | 1 | |
| 2023-08-10 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-040956 | 001-40522 | 231157174 | 34 | 554191 | 1 | 1 |
| 2023-07-26 | 4 | FORM 4 SUBMISSION | 0001209191-23-043408 | 5440 | ||||||
| 2023-07-26 | 3 | FORM 3 SUBMISSION | 0001209191-23-043404 | 7604 | ||||||
| 2023-07-26 | 8-K | 8-K | 5.02 | 0000950170-23-034560 | 001-40522 | 231110074 | 34 | 186859 | 1 | 1 |
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037376 | 5410 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037355 | 5477 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037354 | 5495 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037352 | 5551 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037350 | 5457 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037348 | 5502 | ||||||
| 2023-06-14 | 8-K | 8-K | 5.03,5.07,9.01 | 0000950170-23-027939 | 001-40522 | 231014097 | 34 | 293121 | 1 | 1 |
| 2023-05-11 | 10-Q | 10-Q | 0000950170-23-021201 | 001-40522 | 23910871 | 34 | 7142963 | 1 | 1 | |
| 2023-05-11 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-020846 | 001-40522 | 23908853 | 34 | 484771 | 1 | 1 |
| 2023-04-26 | ARS | ARS | 0000950170-23-014798 | 001-40522 | 23849775 | 34 | 3205701 | |||
| 2023-04-26 | DEFA14A | DEFA14A | 0000950170-23-014787 | 001-40522 | 23849720 | 34 | 3366088 | |||
| 2023-04-26 | DEF 14A | DEF 14A | 0000950170-23-014779 | 001-40522 | 23849643 | 34 | 1574037 | |||
| 2023-04-12 | PRE 14A | PRE 14A | 0000950170-23-012558 | 001-40522 | 23815757 | 34 | 1574200 | |||
| 2023-03-31 | 4 | FORM 4 SUBMISSION | 0001209191-23-021859 | 5421 | ||||||
| 2023-03-24 | 3 | FORM 3 SUBMISSION | 0001209191-23-021072 | 7486 | ||||||
| 2023-03-23 | 8-K | 8-K | 5.02 | 0000950170-23-009320 | 001-40522 | 23754475 | 34 | 185192 | 1 | 1 |
| 2023-03-16 | S-8 | S-8 | 0000950170-23-008471 | 333-270607 | 23738962 | 33 | 221692 | |||
| 2023-03-16 | 10-K | 10-K | 0000950170-23-008440 | 001-40522 | 23738744 | 34 | 21815553 | 1 | 1 | |
| 2023-03-16 | 8-K | 8-K | 2.02,7.01,9.01 | 0000950170-23-008304 | 001-40522 | 23737149 | 34 | 28432502 | 1 | 1 |
| 2023-02-14 | SC 13G/A | sc13g.htm | 0000929638-23-000565 | 005-92649 | 23627760 | 34 | 148199 | |||
| 2023-02-14 | SC 13G/A | glue13gadec22.txt | 0000080255-23-002733 | 005-92649 | 34 | 6884 | ||||
| 2023-02-14 | SC 13G/A | MONTE ROSA THERAPEUTICS, INC. | 0000902664-23-001689 | 005-92649 | 23623545 | 34 | 60399 | |||
| 2023-02-09 | SC 13G/A | filing.txt | 0000315066-23-001955 | 005-92649 | 23604823 | 34 | 8150 | |||
| 2023-02-03 | SC 13G | us61225m1027_020323.txt | 0001306550-23-007642 | 005-92649 | 23586196 | 34 | 13279 | |||
| 2023-01-09 | 8-K | 8-K | 7.01,9.01 | 0000950170-23-000436 | 001-40522 | 23516585 | 34 | 19817703 | 1 | 1 |
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-000958 | 5505 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-000956 | 5489 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-000957 | 5485 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-000952 | 5491 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-000949 | 5592 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-000953 | 5487 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-000951 | 5471 | ||||||
| 2023-01-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-000948 | 5485 | ||||||
| 2022-12-19 | 4 | FORM 4 SUBMISSION | 0001209191-22-061947 | 5704 | ||||||
| 2022-11-10 | 10-Q | 10-Q | 0000950170-22-024447 | 001-40522 | 221377093 | 34 | 8006055 | 1 | 1 | |
| 2022-11-10 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-024165 | 001-40522 | 221374966 | 34 | 487432 | 1 | 1 |
| 2022-11-01 | 4 | FORM 4 SUBMISSION | 0001209191-22-055037 | 5704 | ||||||
| 2022-10-24 | 8-K | FORM 8-K | 7.01,9.01 | 0001193125-22-267232 | 001-40522 | 221324943 | 34 | 9846885 | 1 | 1 |
| 2022-08-11 | 10-Q | 10-Q | 0000950170-22-016844 | 001-40522 | 221155616 | 34 | 7227175 | 1 | 1 | |
| 2022-08-11 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-016647 | 001-40522 | 221153714 | 34 | 2168574 | 1 | 1 |
| 2022-07-13 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2022-07-13 16:00:00 | 9999999995-22-002061 | 333-266003 | 221082144 | 33 | 1735 | ||
| 2022-07-11 | CORRESP | filename1.htm | 0001193125-22-190944 | 5488 | ||||||
| 2022-07-08 | UPLOAD | filename1.pdf | 0000000000-22-007225 | 40225 | ||||||
| 2022-07-01 | S-3 | S-3 | 0001193125-22-187284 | 333-266003 | 221062196 | 33 | 1399830 | |||
| 2022-06-16 | 4 | FORM 4 SUBMISSION | 0001209191-22-037527 | 5375 | ||||||
| 2022-06-16 | 4 | FORM 4 SUBMISSION | 0001209191-22-037432 | 5457 | ||||||
| 2022-06-16 | 4 | FORM 4 SUBMISSION | 0001209191-22-037429 | 5513 | ||||||
| 2022-06-16 | 4 | FORM 4 SUBMISSION | 0001209191-22-037427 | 5419 | ||||||
| 2022-06-16 | 4 | FORM 4 SUBMISSION | 0001209191-22-037421 | 5464 | ||||||
| 2022-06-15 | 8-K | 8-K | 5.07 | 0000950170-22-011697 | 001-40522 | 221018490 | 34 | 205554 | 1 | 1 |
| 2022-06-08 | DEFA14A | DEFA14A | 0000950170-22-011328 | 001-40522 | 221003641 | 34 | 84809 | |||
| 2022-05-11 | 10-Q | 10-Q | 0000950170-22-009324 | 001-40522 | 22913792 | 34 | 6488708 | 1 | 1 | |
| 2022-05-11 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-009141 | 001-40522 | 22912096 | 34 | 2150090 | 1 | 1 |
| 2022-04-28 | DEFA14A | DEFA14A | 0000950170-22-006556 | 001-40522 | 22867158 | 34 | 245881 | |||
| 2022-04-27 | DEF 14A | DEF 14A | 0000950170-22-006371 | 001-40522 | 22859660 | 34 | 1209793 | |||
| 2022-03-29 | S-8 | S-8 | 0001193125-22-088225 | 333-263953 | 22781703 | 33 | 63955 | |||
| 2022-03-29 | 10-K | 10-K | 0000950170-22-004927 | 001-40522 | 22780942 | 34 | 14161669 | 1 | 1 | |
| 2022-03-29 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-004851 | 001-40522 | 22777381 | 34 | 405959 | 1 | 1 |
| 2022-03-02 | 4 | FORM 4 SUBMISSION | 0000899243-22-008711 | 5514 | ||||||
| 2022-03-02 | 4 | FORM 4 SUBMISSION | 0000899243-22-008707 | 5393 | ||||||
| 2022-03-02 | 4 | FORM 4 SUBMISSION | 0000899243-22-008706 | 5404 | ||||||
| 2022-03-02 | 4 | FORM 4 SUBMISSION | 0000899243-22-008705 | 5413 | ||||||
| 2022-03-02 | 4 | FORM 4 SUBMISSION | 0000899243-22-008698 | 5404 | ||||||
| 2022-03-02 | 4 | FORM 4 SUBMISSION | 0000899243-22-008694 | 5409 | ||||||
| 2022-03-02 | 3 | FORM 3 SUBMISSION | 0000899243-22-008691 | 10066 | ||||||
| 2022-03-02 | 4 | FORM 4 SUBMISSION | 0000899243-22-008681 | 5427 | ||||||
| 2022-03-02 | 4 | FORM 4 SUBMISSION | 0000899243-22-008673 | 5411 | ||||||
| 2022-02-14 | SC 13G/A | sc13g.htm | 0000929638-22-000481 | 005-92649 | 22630212 | 34 | 153652 | |||
| 2022-02-11 | SC 13G | MONTE ROSA THERAPEUTICS, INC. | 0000902664-22-001524 | 005-92649 | 22617351 | 34 | 64329 | |||
| 2022-02-10 | SC 13G/A | glue13gajan22.txt | 0000080255-22-000973 | 005-92649 | 34 | 6856 | ||||
| 2022-02-10 | SC 13G | glue13gdec21.txt | 0000080255-22-000962 | 005-92649 | 34 | 6846 | ||||
| 2022-02-09 | SC 13G/A | us61225m1027_020922.txt | 0000834237-22-008617 | 005-92649 | 22608350 | 34 | 12282 | |||
| 2022-02-09 | SC 13G/A | filing.txt | 0000315066-22-001069 | 005-92649 | 22604436 | 34 | 8424 | |||
| 2022-02-04 | SC 13G | us61225m1027_020422.txt | 0000834237-22-007347 | 005-92649 | 22593607 | 34 | 13161 | |||
| 2022-01-10 | 8-K | 8-K | 7.01,9.01 | 0001193125-22-005070 | 001-40522 | 22519699 | 34 | 17202963 | 1 | 1 |
| 2021-12-15 | 8-K | 8-K | 1.01,2.03 | 0001193125-21-357931 | 001-40522 | 211494382 | 34 | 148294 | 1 | 1 |
| 2021-12-02 | 3 | FORM 3 SUBMISSION | 0000899243-21-046613 | 10178 | ||||||
| 2021-11-12 | 8-K | 8-K | 2.02,9.01 | 0001193125-21-326406 | 001-40522 | 211398584 | 34 | 240434 | 1 | 1 |
| 2021-11-10 | 10-Q | 10-Q | 0000950170-21-004138 | 001-40522 | 211397402 | 34 | 7107970 | 1 | 1 | |
| 2021-08-12 | 10-Q | 10-Q | 0000950170-21-001372 | 001-40522 | 211167901 | 34 | 6456759 | 1 | 1 | |
| 2021-08-12 | 8-K | FORM 8-K | 2.02,9.01 | 0000950123-21-010438 | 001-40522 | 211165601 | 34 | 239791 | 1 | 1 |
| 2021-08-10 | SC 13G | filing.txt | 0000315066-21-001693 | 005-92649 | 211158816 | 34 | 8456 | |||
| 2021-07-12 | SC 13D | NEW ENTERPRISE ASSOCIATES 17, L.P. / MONTE ROSA THERAPEUTICS, INC. -- SCHEDULE 1 | 0001072613-21-000469 | 005-92649 | 211085496 | 34 | 530737 | |||
| 2021-07-08 | SC 13D | SC 13D | 0001193125-21-210842 | 005-92649 | 211080516 | 34 | 168635 | |||
| 2021-07-08 | SC 13G | a20210539_sc13g.htm | 0000929638-21-000881 | 005-92649 | 211080214 | 34 | 168006 | |||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044051 | 17906 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044050 | 17948 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044048 | 17910 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044045 | 17818 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044044 | 17953 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044043 | 17923 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044042 | 17912 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044041 | 17916 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044040 | 17950 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044039 | 17902 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044037 | 17914 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044035 | 17816 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-044033 | 20641 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0000899243-21-026769 | 19439 | ||||||
| 2021-06-30 | 4 | FORM 4 SUBMISSION | 0000899243-21-026766 | 28143 | ||||||
| 2021-06-30 | 4 | FORM 4 | 0001567619-21-012781 | 20497 | ||||||
| 2021-06-28 | 8-K | 8-K | 5.03,9.01 | 0001193125-21-202038 | 001-40522 | 211053711 | 34 | 149376 | ||
| 2021-06-25 | 4 | FORM 4 SUBMISSION | 0001209191-21-043356 | 5252 | ||||||
| 2021-06-25 | 4 | FORM 4 SUBMISSION | 0000899243-21-025983 | 8584 | ||||||
| 2021-06-25 | 4 | FORM 4 SUBMISSION | 0000899243-21-025982 | 5313 | ||||||
| 2021-06-25 | 4 | FORM 4 SUBMISSION | 0000899243-21-025981 | 5391 | ||||||
| 2021-06-25 | 4 | FORM 4 SUBMISSION | 0000899243-21-025977 | 8525 | ||||||
| 2021-06-25 | 4 | FORM 4 SUBMISSION | 0000899243-21-025980 | 8532 | ||||||
| 2021-06-25 | 4 | FORM 4 SUBMISSION | 0000899243-21-025976 | 8636 | ||||||
| 2021-06-25 | 4 | FORM 4 SUBMISSION | 0000899243-21-025984 | 8624 | ||||||
| 2021-06-25 | 4 | FORM 4 SUBMISSION | 0000899243-21-025979 | 5405 | ||||||
| 2021-06-25 | 4 | FORM 4 SUBMISSION | 0000899243-21-025978 | 14654 | ||||||
| 2021-06-25 | 4 | FORM 4 SUBMISSION | 0000899243-21-025975 | 5297 | ||||||
| 2021-06-25 | S-8 | S-8 | 0001193125-21-200331 | 333-257406 | 211047675 | 33 | 397169 | |||
| 2021-06-25 | 424B4 | 424B4 | 0001193125-21-199386 | 333-256773 | 211044636 | 33 | 9130325 | |||
| 2021-06-23 | SEC STAFF LETTER | filename1.pdf | 9999999997-21-003614 | 271844 | ||||||
| 2021-06-23 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2021-06-23 16:00:00 | 9999999995-21-002471 | 333-256773 | 211040478 | 33 | 1735 | ||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042883 | 7542 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042882 | 7584 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042880 | 7546 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042878 | 7454 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042876 | 7589 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042875 | 7559 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042874 | 7548 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042873 | 7552 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042871 | 7586 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042869 | 7538 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042868 | 7550 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042866 | 7452 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0001209191-21-042864 | 10729 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025636 | 7599 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025635 | 10070 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025631 | 10015 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025630 | 7687 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025624 | 14979 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025622 | 7605 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025615 | 10719 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025613 | 7662 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025606 | 10079 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025600 | 10923 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025593 | 8932 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025583 | 10115 | ||||||
| 2021-06-23 | 3 | FORM 3 SUBMISSION | 0000899243-21-025575 | 19024 | ||||||
| 2021-06-23 | S-1MEF | S-1MEF | 0001193125-21-197580 | 333-257330 | 211040164 | 33 | 49740 | |||
| 2021-06-23 | 3 | FORM 3 | 0001567619-21-012551 | 14790 | ||||||
| 2021-06-22 | CERT | 8ACERT_GLUE.pdf | 0001354457-21-000689 | 001-40522 | 211034288 | 34 | 161419 | |||
| 2021-06-21 | 8-A12B | 8-A12B | 0001193125-21-195045 | 001-40522 | 211030550 | 34 | 14854 | |||
| 2021-06-21 | CORRESP | filename1.htm | 0001193125-21-195023 | 11788 | ||||||
| 2021-06-21 | CORRESP | filename1.htm | 0001193125-21-195011 | 10449 | ||||||
| 2021-06-21 | CORRESP | filename1.htm | 0001193125-21-194066 | 22824 | ||||||
| 2021-06-21 | S-1/A | S-1/A | 0001193125-21-194056 | 333-256773 | 211027188 | 33 | 10941648 | |||
| 2021-06-15 | UPLOAD | filename1.pdf | 0000000000-21-007359 | 43227 | ||||||
| 2021-06-11 | CORRESP | filename1.htm | 0001193125-21-188875 | 66430 | ||||||
| 2021-06-09 | CORRESP | filename1.htm | 0001193125-21-186843 | 22915 | ||||||
| 2021-06-09 | S-1/A | S-1/A | 0001193125-21-186830 | 333-256773 | 211005694 | 33 | 9207889 | |||
| 2021-06-07 | UPLOAD | filename1.pdf | 0000000000-21-007037 | 46272 | ||||||
| 2021-06-04 | S-1 | S-1 | 0001193125-21-182268 | 333-256773 | 21995093 | 33 | 12630834 | |||
| 2021-05-25 | SEC STAFF LETTER | filename1.pdf | 9999999997-21-003025 | 272646 | ||||||
| 2021-05-21 | DRSLTR | filename1.htm | 0000950123-21-007251 | 48790 | ||||||
| 2021-05-21 | DRS/A | filename1.htm | 0000950123-21-007249 | 377-04684 | 21949640 | 33 | 9173765 |
One latest value per concept from companyfacts (277 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 85.45M | 2026-10-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 212.00M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | AccountsPayableAndOtherAccruedLiabilitiesCurrent | Accounts Payable and Other Accrued Liabilities, Current | USD | 33.41M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 3.35M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 9.00M | 2024-06-30 | 2024 | Q2 | 10-Q | 2024-08-08 | 0000950170-24-093296 | |
| us-gaap | AccruedLiabilitiesAndOtherLiabilities | Accrued Liabilities and Other Liabilities | USD | 1.94M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 33.41M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 33.69M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -6.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 1.06B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 6.32M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | AdministrativeFeesExpense | Administrative Fees Expense | USD | 31.13M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 18.24M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | AmortizationOfIntangibleAssets | Amortization of Intangible Assets | USD | 2.07M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax | Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax | USD | -833,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | Assets | Assets | USD | 697.73M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 640.07M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AssetsFairValueDisclosure | Assets, Fair Value Disclosure | USD | 589.43M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 9,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 2.37M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 534.91M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | AvailableForSaleDebtSecuritiesGrossUnrealizedLoss | Debt Securities, Available-for-sale, Unrealized Loss | USD | 118,000 | 2025-01-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-07 | 0000950170-25-104550 |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 532.55M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 734,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 45.18M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 577.70M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 50.10M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -84.74M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 33.41M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 500.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 85.43M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 85.43M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 9,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -87.20M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | ConvertiblePreferredStockSharesIssuedUponConversion | Convertible Preferred Stock, Shares Issued upon Conversion | shares | 31.07M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 | |
| us-gaap | CurrentFederalStateAndLocalTaxExpenseBenefit | Current Federal, State and Local, Tax Expense (Benefit) | USD | -1.10M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | CurrentFederalTaxExpenseBenefit | Current Federal Tax Expense (Benefit) | USD | -865,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | -232,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DebtSecuritiesAvailableForSaleRealizedGainLoss | Debt Securities, Available-for-sale, Realized Gain (Loss) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | DebtSecuritiesAvailableForSaleRealizedLoss | Debt Securities, Available-for-sale, Realized Loss | USD | 2.53M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | DebtSecuritiesAvailableForSaleUnrealizedGainLoss | Debt Securities, Available-for-sale, Unrealized Gain (Loss) | USD | -1.08M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | DebtSecuritiesAvailableForSaleUnrealizedLossPosition | Debt Securities, Available-for-sale, Unrealized Loss Position | USD | 514.40M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 9.78M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DeferredRevenue | Deferred Revenue | USD | 102.26M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | DeferredRevenueCurrent | Deferred Revenue, Current | USD | 21.10M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 83.41M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 9.78M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 52.87M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 13,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 10.04M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation | USD | 5.43M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 73.63M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DeferredTaxLiabilities | Deferred Tax Liabilities, Net | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities | Liability, Defined Benefit Pension Plan | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-20 | 0000950170-25-042344 | |
| us-gaap | DefinedBenefitPensionPlanLiabilitiesNoncurrent | Liability, Defined Benefit Pension Plan, Noncurrent | USD | 5.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | DefinedBenefitPlanActualReturnOnPlanAssets | Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) | USD | 253,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanActuarialGainLoss | Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) | USD | 833,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanAdministrationExpenses | Defined Benefit Plan, Plan Assets, Administration Expense | USD | 200,000 | 2023-01-01 | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-11 | 0000950170-23-021201 |
| us-gaap | DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate | pure | 0.014 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets | pure | 0.014 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase | pure | 0.013 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanBenefitObligation | Defined Benefit Plan, Benefit Obligation | USD | 17.70M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DefinedBenefitPlanBenefitObligationBenefitsPaid | Defined Benefit Plan, Benefit Obligation, Benefits Paid | USD | 343,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant | Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant | USD | 219,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanContributionsByEmployer | Defined Benefit Plan, Plan Assets, Contributions by Employer | USD | 973,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter | Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years | USD | 7.42M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths | Defined Benefit Plan, Expected Future Benefit Payment, Year One | USD | 1.17M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive | Defined Benefit Plan, Expected Future Benefit Payment, Year Five | USD | 1.27M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour | Defined Benefit Plan, Expected Future Benefit Payment, Year Four | USD | 1.25M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree | Defined Benefit Plan, Expected Future Benefit Payment, Year Three | USD | 1.23M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo | Defined Benefit Plan, Expected Future Benefit Payment, Year Two | USD | 1.20M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DefinedBenefitPlanFairValueOfPlanAssets | Defined Benefit Plan, Plan Assets, Amount | USD | 12.44M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation | Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) | USD | 2.01M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanInterestCost | Defined Benefit Plan, Interest Cost | USD | 9,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 |
| us-gaap | DefinedBenefitPlanNetPeriodicBenefitCost | Defined Benefit Plan, Net Periodic Benefit Cost (Credit) | USD | 1.37M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanOtherChanges | Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change | USD | -26,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | DefinedBenefitPlanPlanAmendments | Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanPlanAssetsBenefitsPaid | Defined Benefit Plan, Plan Assets, Benefits Paid | USD | 343,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant | Defined Benefit Plan, Plan Assets, Contributions by Plan Participant | USD | 219,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss | Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) | USD | 1.42M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedBenefitPlanServiceCost | Defined Benefit Plan, Service Cost | USD | 1.23M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | DefinedContributionPlanEmployerDiscretionaryContributionAmount | Defined Contribution Plan, Employer Discretionary Contribution Amount | USD | 1.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | DefinedContributionPlanEmployerMatchingContributionPercent | Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | pure | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | DefinedContributionPlanEmployerMatchingContributionPercentOfMatch | Defined Contribution Plan, Employer Matching Contribution, Percent of Match | pure | 0.04 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | Depreciation | Depreciation | USD | 6.09M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | DividendsPayableCurrentAndNoncurrent | Dividends Payable | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | DividendsPreferredStockStock | Dividends, Preferred Stock, Stock | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | 0.51 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-11 | 0000950170-22-009324 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0.028 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.007 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent | pure | -0.036 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-20 | 0000950170-25-042344 |
| us-gaap | EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent | pure | -0.056 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-20 | 0000950170-25-042344 |
| us-gaap | EffectiveIncomeTaxRateReconciliationGiltiAmount | EffectiveIncomeTaxRateReconciliationGiltiAmount | USD | -70,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationGiltiPercent | EffectiveIncomeTaxRateReconciliationGiltiPercent | pure | 0.002 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | -0.003 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.139 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent | pure | -0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0.005 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsOther | Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent | pure | 0.002 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-20 | 0000950170-25-042344 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | 0.047 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 9.33M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | USD | 25.10M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 | |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations | FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations | USD | -1.10M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | FinanceLeaseLiability | Finance Lease, Liability | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | FinancialLiabilitiesFairValueDisclosure | Financial Liabilities Fair Value Disclosure | USD | 19.68M | 2020-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 | |
| us-gaap | ForeignCurrencyTransactionGainLossBeforeTax | Foreign Currency Transaction Gain (Loss), before Tax | USD | 110,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | GainLossOnDispositionOfAssets1 | Gain (Loss) on Disposition of Assets | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | GainLossOnSaleOfPropertyPlantEquipment | Gain (Loss) on Disposition of Property Plant Equipment | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 31.25M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | ImpairmentOfLongLivedAssetsHeldForUse | Impairment of Long-Lived Assets Held-for-use | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | ImpairmentOfLongLivedAssetsToBeDisposedOf | Impairment of Long-Lived Assets to be Disposed of | USD | 100,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -23.08M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -83.86M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | -16.65M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncomeLossFromContinuingOperationsPerBasicShare | Income (Loss) from Continuing Operations, Per Basic Share | USD/shares | -0.84 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | IncomeLossFromContinuingOperationsPerDilutedShare | Income (Loss) from Continuing Operations, Per Diluted Share | USD/shares | -0.84 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 5.18M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 976,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | IncomeTaxPaidFederalAfterRefundReceived | IncomeTaxPaidFederalAfterRefundReceived | USD | 4.61M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncomeTaxPaidStateAndLocalAfterRefundReceived | IncomeTaxPaidStateAndLocalAfterRefundReceived | USD | 572,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 259,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -8.31M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 97,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 5.48M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncomeTaxReconciliationOtherReconcilingItems | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount | USD | 44,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | -183,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | -1.85M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | -519,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | 0 | 2025-01-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-07 | 0000950170-25-104550 |
| us-gaap | IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities | USD | 6.45M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | IncreaseDecreaseInDeferredRevenue | Increase (Decrease) in Deferred Revenue | USD | -17.54M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | IncreaseDecreaseInOperatingLeaseLiability | IncreaseDecreaseInOperatingLeaseLiability | USD | -1.88M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | IncreaseDecreaseInOtherOperatingAssets | Increase (Decrease) in Other Operating Assets | USD | 6.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 |
| us-gaap | IncreaseDecreaseInOtherReceivables | Increase (Decrease) in Other Receivables | USD | 3.02M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 853,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | InterestExpenseOther | Interest Expense, Other | USD | 140,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | InterestIncomeExpenseNonoperatingNet | Interest Income (Expense), Nonoperating, Net | USD | 17.13M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | LaborAndRelatedExpense | Labor and Related Expense | USD | 13.49M | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-07 | 0001193125-26-210358 |
| us-gaap | LandSubjectToGroundLeases | Land Subject to Ground Leases | sqft | 63,327 | 2021-12-14 | 2022 | Q1 | 10-Q | 2022-05-11 | 0000950170-22-009324 | |
| us-gaap | LeaseAndRentalExpense | Operating Leases, Rent Expense | USD | 2.30M | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 |
| us-gaap | LeaseCost | Lease, Cost | USD | 7.12M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | Liabilities | Liabilities | USD | 201.52M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 697.73M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 62.05M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | MarketableSecurities | Marketable Securities | USD | 532.55M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | MarketableSecuritiesGainLoss | Marketable Securities, Gain (Loss) | USD | 0 | 2024-01-01 | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-09 | 0000950170-24-056288 |
| us-gaap | MarketableSecuritiesRealizedGainLoss | Marketable Securities, Realized Gain (Loss) | USD | 0 | 2024-01-01 | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-09 | 0000950170-24-056288 |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 332.11M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -294.39M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -122.46M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -84.84M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 17.24M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-06 | 0001193125-26-336711 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 168.65M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -101.10M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 4.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 7.12M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 7.40M | 2022-01-01 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 4.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 32.08M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 23.34M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 81.00M | 2021-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 8.35M | 2021-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFiveYears | Operating Leases, Future Minimum Payments, Due in Five Years | USD | 7.30M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 7.30M | 2021-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 8.82M | 2021-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 8.58M | 2021-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueThereafter | Operating Leases, Future Minimum Payments, Due Thereafter | USD | 44.78M | 2021-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 3.16M | 2021-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 | |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.098 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 767,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentBeforeTaxPortionAttributableToParent | Other Comprehensive (Income) Loss, Defined Benefit Plan, before Tax, after Reclassification Adjustment, Attributable to Parent | USD | -1.59M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | 500,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax | USD | 756,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax | USD | -161,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | OtherGeneralAndAdministrativeExpense | Other General and Administrative Expense | USD | 10.11M | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-07 | 0001193125-26-210358 |
| us-gaap | OtherLiabilitiesCurrent | Other Liabilities, Current | USD | 1.65M | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-06 | 0001193125-25-268045 | |
| us-gaap | OtherOwnershipInterestsOfferingCosts | Other Ownership Interests, Offering Costs | USD | 1.00M | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 | |
| us-gaap | OtherReceivables | Other Receivables | USD | 4.61M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-07 | 0001193125-26-210358 | |
| us-gaap | OtherReceivablesNetCurrent | Other Receivables, Net, Current | USD | 7.62M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | OtherResearchAndDevelopmentExpense | Other Research and Development Expense | USD | 35.11M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | PaymentOfFinancingAndStockIssuanceCosts | Payment of Financing and Stock Issuance Costs | USD | 357,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | PaymentsForRent | Payments for Rent | USD | 95 | 2021-12-14 | 2022 | Q1 | 10-Q | 2022-05-11 | 0000950170-22-009324 | |
| us-gaap | PaymentsForRepurchaseOfInitialPublicOffering | Payments for Repurchase of Initial Public Offering | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 |
| us-gaap | PaymentsForTenantImprovements | Payments for Tenant Improvements | USD | 13.00M | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-06 | 0001193125-25-268045 |
| us-gaap | PaymentsOfDividends | Payments of Dividends | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 290,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 499.78M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 8.15M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent | Liability, Defined Benefit Plan | USD | 5.26M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | PensionExpense | Pension Cost (Reversal of Cost) | USD | 1.11M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 10.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-14 | 0000950170-24-031150 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-14 | 0000950170-24-031150 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 4.71M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 0 | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-06 | 0001193125-25-268045 |
| us-gaap | ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan | Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan | USD | 527,000 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-20 | 0000950170-25-042344 |
| us-gaap | ProceedsFromIssuanceOfConvertiblePreferredStock | Proceeds from Issuance of Convertible Preferred Stock | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 |
| us-gaap | ProceedsFromIssuanceOfWarrants | Proceeds from Issuance of Warrants | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | ProceedsFromIssuanceOrSaleOfEquity | Proceeds from Issuance or Sale of Equity | USD | 345.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | ProceedsFromSaleAndMaturityOfMarketableSecurities | Proceeds from Sale and Maturity of Marketable Securities | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-20 | 0000950170-25-042344 |
| us-gaap | ProceedsFromSaleOfPropertyPlantAndEquipment | Proceeds from Sale of Property, Plant, and Equipment | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-20 | 0000950170-25-042344 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 7.69M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | ProfessionalAndContractServicesExpense | Professional and Contract Services Expense | USD | 6.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -84.84M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 62.33M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 28.63M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 137.40M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | RestrictedCash | Restricted Cash | USD | 4.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | RestrictedCashAndCashEquivalents | Restricted Cash and Cash Equivalents | USD | 326.10M | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-08 | 0000950170-25-066372 | |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-14 | 0000950170-24-031150 | |
| us-gaap | RestrictedCashNoncurrent | Restricted Cash, Noncurrent | USD | 4.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -562.05M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | RevenueFromContractWithCustomerIncludingAssessedTax | Revenue from Contract with Customer, Including Assessed Tax | USD | 67.54M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 18.24M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | USD | 1.50M | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 0.841 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.044 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 45.91M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 9.78M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 8.12 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 1.62M | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-10 | 0000950170-21-004138 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 127,377 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 2.94M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 5.16 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 62.72M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 15.87M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 9.22 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | USD | 62.72M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | USD/shares | 9.22 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | USD | 82.19M | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-10 | 0000950170-21-004138 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 5.57M | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-10 | 0000950170-21-004138 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | USD/shares | 7.58 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-10 | 0000950170-21-004138 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares | 15.87M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | USD/shares | 1.13 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 7.62 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 9.71 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 15.73 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | SharesIssuedPricePerShare | Shares Issued, Price Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | ShortTermLeaseCost | Short-term Lease, Cost | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-20 | 0000950170-25-042344 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 496.21M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 | |
| us-gaap | StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities | Stock Issued During Period, Shares, Conversion of Convertible Securities | shares | 31.07M | 2021-06-01 | 2021-06-30 | 2022 | Q1 | 10-Q | 2022-05-11 | 0000950170-22-009324 |
| us-gaap | StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans | Stock Issued During Period, Shares, Employee Stock Purchase Plans | shares | 46,960 | 2026-04-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-06 | 0001193125-26-336711 |
| us-gaap | StockIssuedDuringPeriodSharesNewIssues | Stock Issued During Period, Shares, New Issues | shares | 13.00M | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-07 | 0001193125-26-210358 |
| us-gaap | StockIssuedDuringPeriodSharesOther | Stock Issued During Period, Shares, Other | shares | 0 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-20 | 0000950170-25-042344 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 1.01M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 231.17M | 2021-04-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-12 | 0000950170-21-001372 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfUnits | Stock Issued During Period, Value, Conversion of Units | USD | 231.17M | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008440 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 611,000 | 2026-04-01 | 2026-06-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | StockIssuedDuringPeriodValueIssuedForServices | Stock Issued During Period, Value, Issued for Services | USD | 87,000 | 2024-01-01 | 2024-03-31 | 2025 | Q1 | 10-Q | 2025-05-08 | 0000950170-25-066372 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 323.81M | 2026-01-01 | 2026-03-31 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 568,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 325.88M | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-11 | 0000950170-22-009324 | |
| us-gaap | TemporaryEquityParOrStatedValuePerShare | Temporary Equity, Par or Stated Value Per Share | USD/shares | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 | |
| us-gaap | TemporaryEquitySharesAuthorized | Temporary Equity, Shares Authorized | shares | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 | |
| us-gaap | TemporaryEquitySharesIssued | Temporary Equity, Shares Issued | shares | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 | |
| us-gaap | TemporaryEquitySharesOutstanding | Temporary Equity, Shares Outstanding | shares | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 | |
| us-gaap | TemporaryEquityValueExcludingAdditionalPaidInCapital | Temporary Equity, Par Value | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-29 | 0000950170-22-004927 | |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 | |
| us-gaap | UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 1.50M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001193125-26-109360 |
| us-gaap | VariableLeaseCost | Variable Lease, Cost | USD | 2.17M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 101.06M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 46.60M | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-11 | 0000950170-22-009324 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 101.06M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-448568 |